Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study

References

• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report. Respirology. 2017;22:575–601.28150362
   PubMed Web of Science ®Google Scholar
• World Health Organization. The global burden of disease, 2004 update http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=1.
   Google Scholar
• FangX, WangX, BaiC. COPD in China: the burden and importance of proper management. Chest. 2011;139:920–929. doi:10.1378/chest.10-139321467059
   PubMed Web of Science ®Google Scholar
• G. BD. Causes of death collaborators. global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1151–1210. doi:10.1016/S0140-6736(17)32152-928919116
   PubMed Web of Science ®Google Scholar
• GuarascioAJ, RaySM, FinchCK, SelfTH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. CEOR. 2013;5:235–245. doi:10.2147/CEOR.S34321
   Google Scholar
• FangL, GaoP, BaoH, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Res Med. 2018;6:421–430. doi:10.1016/S2213-2600(18)30103-6
   PubMed Web of Science ®Google Scholar
• YangG, WangY, ZengY, et al. Rapid health transition in China, 1990–2010: findings from the global burden of disease Study 2010. Lancet. 2013;381:1987–2015. doi:10.1016/S0140-6736(13)61097-123746901
   PubMed Web of Science ®Google Scholar
• TanWC, NgTP. COPD in Asia: where east meets west. Chest. 2008;133:517–527. doi:10.1378/chest.07-113118252918
   PubMed Web of Science ®Google Scholar
• HeQY, ZhouX, XieCM, LiangZA, ChenP, WuCG. [Impact of chronic obstructive pulmonary disease on quality of life and economic burden in Chinese urban areas]. Zhonghua Jie He He Hu Xi Za Zhi. 2009;32:253–257.19576036
   PubMedGoogle Scholar
• RestrepoRD, AlvarezMT, WittnebelLD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:371–384. doi:10.2147/COPD.S303618990964
   PubMedGoogle Scholar
• StuartBC, Simoni-WastilaL, ZuckermanIH, et al. Impact of maintenance therapy on hospitalization and expenditures for medicare beneficiaries with chronic obstructive pulmonary disease. Am J Geriatr Pharmacother. 2010;8:441–453. doi:10.1016/j.amjopharm.2010.10.00221335297
   PubMedGoogle Scholar
• SanduzziA, BalboP, CandoliP, et al. COPD: adherence to therapy. Multidiscip Respir Med. 2014;9:60. doi:10.1186/2049-6958-9-6025485108
   PubMedGoogle Scholar
• van BovenJF, ChavannesNH, van der MolenT, Rutten-van MolkenMP, PostmaMJ, VegterS. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108:103–113. doi:10.1016/j.rmed.2013.08.04424070566
   PubMed Web of Science ®Google Scholar
• YuH. Universal health insurance coverage for 1.3 billion people: what accounts for China’s success? Health Policy. 2015;119:1145–1152. doi:10.1016/j.healthpol.2015.07.00826251322
   PubMed Web of Science ®Google Scholar
• Simoni-WastilaL, WeiYJ, QianJ, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a medicare population. Am J Geriatr Pharmacother. 2012;10:201–210. doi:10.1016/j.amjopharm.2012.04.00222521808
   PubMed Web of Science ®Google Scholar
• VestboJ, LeatherD, Diar BakerlyN, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375:1253–1260. doi:10.1056/NEJMoa160803327593504
   PubMed Web of Science ®Google Scholar
• ShenY, CaiW, LeiS, ZhangZ. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis. Copd. 2014;11:351–358. doi:10.3109/15412555.2013.85831524378052
   PubMedGoogle Scholar
• CazzolaM, CalzettaL, PageC, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Res. 2015;24:451–461. doi:10.1183/16000617.00002215
   Google Scholar
• DecramerM, Rutten-van MolkenM, DekhuijzenPN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on NAC cost-utility study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365:1552–1560. doi:10.1016/S0140-6736(05)66456-215866309
   PubMed Web of Science ®Google Scholar
• SchermerT, ChavannesN, DekhuijzenR, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009;103:542–551. doi:10.1016/j.rmed.2008.11.00319138505
   PubMed Web of Science ®Google Scholar
• MiaoY, GuJ, ZhangL, HeR, SandeepS, WuJ. Improving the performance of social health insurance system through increasing outpatient expenditure reimbursement ratio: a quasi-experimental evaluation study from rural China. Int J Equity Health. 2018;17:89. doi:10.1186/s12939-018-0799-829940956
   PubMed Web of Science ®Google Scholar
• ZhangR, HeQ. Awareness of knowledge of COPD by doctors in district and community hospitals. Chin J Prev Control Chronic Dis. 2009;17:61–63.
   Google Scholar
• BengtsonLGS, DePietroM, McPheetersJ, FoxKM. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy. Ther Adv Respir Dis. 2018;12:1753466618772750. doi:10.1177/175346661877275029737943
   PubMed Web of Science ®Google Scholar
• MoretzC, SharpstenL, BengtsonLG, et al. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1721–1737. doi:10.2147/COPD.S20464931534326
   PubMed Web of Science ®Google Scholar
• HalpinDMG, de JongHJI, CarterV, SkinnerD, PriceD. Distribution, temporal stability and appropriateness of therapy of patients with COPD in the UK in relation to GOLD 2019. E Clin Med. 2019;14:32–41. doi:10.1016/j.eclinm.2019.07.003
   Web of Science ®Google Scholar
• Gruffydd-JonesK, BrusselleG, JonesR, et al. Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational. NPJ Prim Care Res Med. 2016;26:16002. doi:10.1038/npjpcrm.2016.2
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonJA, CalverleyPM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939–943. doi:10.1136/thx.2009.11366219703830
   PubMed Web of Science ®Google Scholar
• ToyEL, BeaulieuNU, McHaleJM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435–441. doi:10.1016/j.rmed.2010.09.00620880687
   PubMed Web of Science ®Google Scholar